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A 10B-dopa analogue, 10B1-para-boronophenylalanine 
e0B 1 -BPA) has been found to have a marked melanoma 
killing effect as expressed by the Do value, 0.9-1.2 x 1012 
njcm2 • The Do value of the neutron alone is 2.8 x 1012 n/ 
cm2 • 
After the introduction of high LET irradiation into 
radiotherapy, its higher energy deposition in the target 
cancer cells is one of the major problems currently to be 
solved. This can be achieved by our thermal neutron 
capture therapy in the order of cellular dimentions when 
we have highly tumor-seeking 10B-compounds available. 
Our present evidence seems to indicate that our new 
tOB 1-BP A can highly concentrate 10B into melanoma cells, 
to as much as 11 times the level of the medium in the in 
vitro system. 
The objective of this study is to establish the selective ther-
mal neutron capture treatment of malignant melanoma as 
a prototype of such cancer cells having specific functional 
differentiation. Our investigation is based on the following idea 
[1,2]. Melanoma is the cancerous growth of the pigment cell. 
There are not only malignant melanoma, but also many kinds 
of human cancers, for example thyroid cancer and squamous 
cell carcinoma, having cellular functional differentiation syn-
thesizing their specific protein. Cancer cells are well determined, 
being incapable of producing anything but more cancer cells of 
their own kind, in contrast to the normal cells which have 
pluripotentiality [3]. As malignant transformation occurs, they 
usually acquire an increased tyrosinase activity and generally 
well retain the melanin synthesizing ability in the majority of 
cases [2). Using this cellular property, we [1,2,4) developed this 
treatment after we had successfully synthesized molecular hy-
brid compounds of 10B atoms and chlorpromazine which bind 
selectively with indole nucli of melanine [5,6, 7], and also a 
number of molecular hybrids of 10B and dopa, substrate for 
melanin. 
Thermal neutrons are absorbed easily by 10B, and this results 
in the emmision of high LET a-particles and lithium atoms 
sharing between them an average total kinetic energy of 2.33 
Me V[8], which transfers totally to the tissues. Due to the 
limited travelling range of these charged particles, the primary 
radiation injury is confined within a distance of 10-14 J.t from 
the point of the activated boron atom. This distance is almost 
equal to the diameter of individual melanoma cells. Therefore 
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our objectives are to selectively accumulate 10B in melanoma 
cells, and to erradicate them with thermal neutron irradiation 
without serious injury to the surrounding normal tissues. 
In 1976 [2] we published the distinct suppressive effects of 
the thermal neutron capture treatment on the tumor growth of 
melanoma bearing hamsters, using "B12-chlorpromazine ("Bl2-
CPZ) (9). Recently, we have been able to suppress the mela-
noma growth completely for 15-20 days after irradiation using 
t he boron-10 enriched 10B12-CPZ, while the tumors of the con-
trol group treated by the thermal neutron alone ceased to grow 
for only 4-7 days (4). The main cause of the tumor regrowth 
could be thought to be nonhomogenous incorporation of 10B-
compound due to polyclonal population of melanoma cells. 
In the course of our studies on thermal neutron capture 
therapy of melanoma with 10B1z-CPZ, we [10] have developed 
an in vitro radiobiological analysis system using cultured B-16 
melanoma cells and this compound. Furthermore, in this in 
vitro system we have demonstrated that the selective affinity 
of CPZ to melanoma cells is parallels to their melanin content 
at the cellular level. 
In order to prevent the regrowth of melanoma after the 
capture therapy with 10B 12-CPZ, we have also synthesized hy-
brid compounds of 10B atom and dopa which is the substrate of 
tyrosinase, a melanin forming enzyme. The 3 compounds, 10B 1-
dopa borate, "B 1-para-boronophenylalanine ("B1-BPA), and 10B 1-para-boronophenylalanie ('0B 1-BPA) have been synthe-
sized by our research group [ll), according to the method 
described by Snyder, Reedy, and Lennarj (12). Radiobiological 
analysis of the specific or enhancing killing effects of these dopa 
related compounds on melanoma cells in capture therapy has 
been carried out using the culture system. 
MATERIALS AND METHODS 
Cell Lines 
B-16 melanoma cells, a pigmented line, were obtained from Dr. 
Oikawa who characterized and described the melanogenic activity of 
the cell line [13]. The cells have been maintained in our laboratory in 
Eagle's MEM supplemented with 10% fetal calf serum. They were fairly 
pigmented with a tyrosinase activity of about 0.05 E/ 10 min/ mg protein, 
assayed by spectrophotometry [14] and a melanosome content of 
around 0.03 mg protein of melanosome/ mg protein of cells measured 
by Steinberg and Whittaker's methods [15]. 
Neutron Source 
As the sow·ce of the thermal neutrons, the Thermal Column of the 
Kyoto University Nuclear Reactor (KUR) was used. The thermal 
neutron flux of KUR was 7.9 X 108n/cm2 ·s-MW with a negligible 
amount of fast neutrons. The core gamma rays were reduced to 15.0 
rad/ h. MW at the bismuth surface by using the bismuth scatterer 
method of Kanda et al [16]. 
Dosimetry 
The thermal neutron fluences were measured by gold foil activation 
analysis. The mean value of 3 points was taken as the fluence for each 
flask which was located at a different distance from the bismuth surface. 
The accompanied gamma ray dose was measured for each flask using 
a thermoluminescence detector of Mg2SiO.(Tb). 
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Boron Compounds 
The 10B 1-dopa borate used in our study is synthesized in co-operation 
wit h the Kyowahakko Company. "B,-BPA, 10B 1-BPA, and 10B ,-BPA· 
HC1 are synthesized by Kakihana et al of our research group according 
to Snyder's method [12]. 10B 1-BPA . HC1 is a readily water-soluble form 
of "'B 1-BPA. 10B 1-BPA·HC1 has been shown to have high affinity to 
melanogenically active melanotic melanoma as compared to amelanotic 
melanoma.• 10B, -BPA contains approximately 5 times more 10B atom 
than "B,-BPA, which contains natural boron. The 10B enrichment is 
92.4 1%. '"B 1-dopa borate is dissociable at neutral pH and at the low 
concentrations used in this experiment [Fig 1]. 
Quantitative Study of '"B per Gram Wet Weight Cultured Cells 
In order to evaluate the specific killing effects of the '"B,-BPA, we 
established the condensation of 10B in cultured melanoma cells by 
comparing it to the 10B content in the preincubation medium. 
The B-16 melanoma cells in the late exponential phase were prein-
cubated with medium containing 10 !J.g 10B 1-BPA·HC1/ml (0.38 '"B/ml) 
for 20 hr in the incubator. After discarding the medium, the cells were 
cultured in fresh normal medium for 5-6 hr before harvesting. The cells 
from 10 Petri dishes were washed once with phosphate buffered saline 
and collected by trypsin treatment. The chemical assay of the "'B 
content was done in co-operation with Yoshino, Okamoto and Kaki-
hana.i' The concentration of '0B atoms within the cells was expressed 
as !J.g/cell number. 
In order to convert "'B content/number of cultured cells to "'B 
content/gm wet weight cultured cells, we have determined the protein 
amounts per cultured melanoma cell as well as per gram wet melanoma 
tissue by Lowry's method, since the number of cultured cells per gram 
wet weight varies according to the method of centrifugation used to 
collect the cells. 
Thermal Neutron Capture Experiments 
T he fo llowing 3 experiments were carried out to determined the 
specific enhancing killing effects of 10B 1-BPA in the thermal neutron 
capture treatment of malignant melanoma cells. 
1. T hermal neutron irradiation only: The cells in the flasks were set 
at different distances from the bismuth surface of the reactor and 
irradiated for 60 min on the graphite table, to receive the appropriate 
dose of thermal neutron. The temperature of the irradia tion room 
showed a s light rise from 20°C to 28°C during irradiation. The medium 
volume used during the irradiation was 4 ml to reduce the secondary 
gamma rays, therefore the flasks were set horizontally on the graphite 
table as mentioned in the previous paper [10]. After irradiation, an 
appropriate number of cells were plated in triplicate and incubated for 
7 days at 37°C in a humidified atmosphere containing 5% C02. The 
number of colonies consisting of more than 50 cells was coun ted to 
obtain~the dose-survival curves. 
2. Thermal neutron irradiation with "'B,-BPA preincubation: The 
cells were preincubated for 20 hr in 5 ml of medium containing 10 !J.g 
'"B,-BPA/ml (0.44 !J.g10B/ml) . The postincubat ion period with normal 
medium before irradiation was 1 or 6 hr. Thereafter, the cells were 
irradiated in the same manner as described below. 
3. The comparative studies using "B ,-BPA and '"B, -dopa borate: 
Preincubation with "'B nonenriched "B 1-BP A was carried out in 5 ml 
of medium also containing 10 !J.g "B 1-BPA/ml (0.09 llg "'B/ml). 
The preincubation with easily dissociable wB ,-dopa borate was done 
in 5 ml of medium also containing 10 !J.g 10B 1-dopa borate/ml (0.35 !J.g 
'"B/ml). After the 6 hr postincubation period, the irradiation was 
carried out in the same manner. 
RESULTS 
Enhanced Killing Effects of 10B 1-BPA in the Thermal 
Neutron Capture Treatment 
' Cell survival curves of B-16 melanoma ce).ls obtained after 
t h e irradiation with thermal neutrons with and without t h e 
· 
10B 1-BPA preincubation are shown in Fig 2. They exhibit no 
shoulder in e it h er system. The Do value of the thermal neutron 
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a lone is 2.8 X 1012 n /cm2. The Do value of the thermal n eutron 
irradiation with 10B1 -BPA preincubation followe d by one and 6 
hr postincubation are 0.9 X 1012 n/cm 2 and 1.2 X 1012 n /cm 2, 
respectively. The to tal gamma ray dose inclusive of cor e and 
secondary is found to be between 139 rad at a flu e n ce of 5.18 
x 1012 n/cm2, a nd 113 rad at 0.84 X 1012 n /cm 2. 
Killing Effects of"B1-BPA and 10B1-dopa Borate in the 
Capture Treatment 
The Do value of the survival curve obtained from irradiation 
with "B 1-BPA preincubation is 2.1 X 1012 n/cm 2 (Fig 2), whereas 10B 1-dopa borate h as no enhanced killing effect at a con centra-
tion of 10 llg/ml in the capture treatment (Fig 3). 
Determination of the Concentration of 10 B atom in the 
Cultured B -16 Melanoma Cells 
The total number of cells collected from 10 Petri dish (Falcon 
3024) is 3 .8 X 107 in the 10B containing cell series. The 10B 
concentration estimated by ch e mical analysis was 0.44 /lg/3 .8 
X 107 in the cells cultured with 10B1-BPA · HC1, while no 10B is 
detected in the cells cultured without 10B c he micals. 
1 ) 10 8, -Para-boronophenylalanine ·HCI 
( 108,-8PA · HCI) 
2 ) " 8, -Para -boronophenylalanine · HCI 
("8,-8PA ·HCI) 
3) 10 8-dopa borate 
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FIG 1. Chemical structures of "'B-compounds. These chemicals were 
synthesized by our group and used in this study. 
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FIG 2. The cells were irradiated with or without '"B ,-BPA or "B1-
BPA 20 hr preincubation followed by 6 hr (e) or 1 hr (()) postincubat ion 
with fresh normal medium. (6) shows the experiment preincubated 
with ''B, -BPA. The number of colonies was counted to obtain the dose 
survival curve. Each point represents the mean values of the triplicate 
plates, being their standard errors in the range from 2.2 to 9.5. 
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FIG 3. Survival curves for B-16 melanoma cells irradiated with ('f) 
or without (0 ) 10B,-dopa borate. 
In order to convert 0.44 JLg 10B/3.8 X 107 cells to 10B content/ 
gm wet cells, we have determined the amount of gram protein 
number of cells and the amount of gram protein/gram wet 
melanoma tissue. 
2.54 x 106 cultured melanoma cells have been found to 
contain 1.0 mg protein. Thus, 3.68 X 108 cells are calculated to 
be 1.0 gm wet melanoma tissue. 
DISCUSSION 
There have been many attempts to erradicate malignant 
melanoma using tumor seeking chemicals as chemotherapeutic 
agents which have a specific affinity for its usually accelerated 
melanogenesis, such as phenylalanine mustard [17], levodopa 
[18], dopamine [19], dihydroxyindole [20], and y-1-glutamyl-4-
hydroxybenzene [21]. 
Despite the profound interest and efforts among melanoma 
investigators since the first introduction of phenylalanine mus-
tard in the 1950's [22], therapeutic erradication of human 
melanoma has not yet been achieved. Further significant prog-
ress in this line would require the synthesis of the new antitu-
mor agents which can form stable hybrid compounds with 
melanoma seeking chemicals. 
In addition to the selective melanoma-affmity of the com-
pound itself, our thermal neutron capture therapy can multiply 
such selectivity not only by the collimation of the thermal 
neutron beam onto the melanoma, but also by the confinement 
of the released energy in the order of cellular dimensions from 
each activated 10B atom. 
In early 1980, thermal neutron capture treatments of cultured 
melanoma cells using 10B1-CPZ preincubation have already 
been proved to be highly effective in killing melanoma cells 
[10]. The Do value, 1.2 X .1012 n/cm2 of thermal neutron 
irradiation with 10B1-BPA preincubation at a concentration of 
10 JLg/ml (0.44 p.g 10B/ml) is defmitely lower than that of 
neutron irradiation alone, 2.8 X 1012 n/cm2 (Fig 3). Furthermore, 
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the specific enhanced killing effect of 10Bt-BPA in capture 
therapy is apparent by the fact that the Do value of the "B1-
BPA experiment is 2.1 X 1012 n/cm2 parallel to the degree of 
10B-enrichrnent per molecule. It may be compared with our 
previous similar experiments using 10B12-chlorpromazine {'0B 12-
CPZ) preincubation which required 1.1 JLg 10B/ml medium in 
order to obtain similar Do value of 0.9 x 1012 n/cm2 [10]. 
The fmal success of the thermal neutron capture therapy 
requires information on the distribution of 10B in target cancer 
cells. Thus, we have also previously investigated the amount of 
10B necessary to obtain the same Do value, 0.9 X 1012 n/ cm2, 
when we incubated with 10B compounds such as 10B boric acid 
with no specific affinity for melanoma cells, during irradiation. 
It was found that 5 JLg 10B/ml is required to get such a Do value 
[10].t Davis et al [23] reported, based on the chemical assay, 
that the 10B content of the cells cultured with 10B boric acid 
was found to be equal to that of the medium. In the present 
investigation we have found that the killing effects of thermal 
neutron irradiation using 10B 1-BPA preincubation at 10 JLg/ ml 
medium (0.44 JLg 10B/ml) is approximately equal to that ob-
tained by the 10B boric acid co-incubation (5 JLg 10B/ ml). This 
evidence seems to indicate that 10B 1-BPA is selectively incor-
porated and condensed into the melanoma cells 11 times the 
concentration of the 10B 1-BP A in the preincubation medium. 
Furthermore, the chemical assay has revealed that the mela-
noma cells which were preincubated with 10 JLg 10B 1-BPA/ ml 
(0.38 JLg 10B/ml) contained 4.27 !Lg 10B/gm wet cells (approxi-
mately 11 times concentrated compared to preincubation me-
dium) . 
This value is calculated based on the number of melanoma 
cells/mg protein and the wet weight melanoma tissue/ mg pro-
tein. Thus, it may be stated that radiobiological analysis and 
10B assay in our present in vitro experimental system coincide 
well, although we are further studying other influencing factors 
such as the intracellular 10B distribution for 10B 1-BPA and the 
effects of extracellular 10B's for 10B boric acid. 
Concerning the affinity of 10B1-BPA . HCl to melanoma cells, 
it seems apparent from comparative 10B assay in melanotic and 
amelanotic melanoma that our 10B-compound is selectively 
effective in the capture therapy of melanotic melanoma through 
its melanin synthesizing activity. 
The high melanoma affmity of 10B1 -BPA found in the present 
in vitro system further coincides with in vivo studies of thermal 
neutron capture therapy using melanoma bearing hamsters, 
which have revealed the high selective affinity of 10B 1-BPA for 
melanoma tissue, and its marked killing effect on melanoma 
growth [ 4]. § 
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